INTRODUCTION: Recent advancements in the management of colorectal liver metastases have resulted in an improvement in survival. Novel biomarkers such as KRAS, and their mutations potentially predict the response of biological therapies such as cetuximab (Erbitux). This paper evaluates the use of cetuximab in the first-line management of colorectal liver metastases. METHODS: An electronic literature search was performed of publications within the past 6 years. The following key words, singly or in combination, were used: KRAS, cetuximab, metastatic colorectal cancer and colorectal liver metastases. All randomized controlled trials and cohort studies were included. RESULTS: Fifteen prospective studies reviewed the clinical application of cetuximab. Seven studies included sub-group analysis of KRAS mutational status, with only one study performed prospectively. Until the MRC COIN trial, the evidence consistently demonstrated cetuximab significantly improved progression-free survival, overall survival and surgical resection rates, especially in KRAS wild-type tumours. However, the MRC COIN trial found cetuximab had no additional benefit when combined with standard chemotherapy. CONCLUSIONS: The literature does not support the routine use of cetuximab as the standard first-line treatment of colorectal liver metastases, rather highlighting the need for the optimization of treatment on an individual basis, especially depending on tumour KRAS status.
INTRODUCTION: Recent advancements in the management of colorectal liver metastases have resulted in an improvement in survival. Novel biomarkers such as KRAS, and their mutations potentially predict the response of biological therapies such as cetuximab (Erbitux). This paper evaluates the use of cetuximab in the first-line management of colorectal liver metastases. METHODS: An electronic literature search was performed of publications within the past 6 years. The following key words, singly or in combination, were used: KRAS, cetuximab, metastatic colorectal cancer and colorectal liver metastases. All randomized controlled trials and cohort studies were included. RESULTS: Fifteen prospective studies reviewed the clinical application of cetuximab. Seven studies included sub-group analysis of KRAS mutational status, with only one study performed prospectively. Until the MRC COIN trial, the evidence consistently demonstrated cetuximab significantly improved progression-free survival, overall survival and surgical resection rates, especially in KRAS wild-type tumours. However, the MRC COIN trial found cetuximab had no additional benefit when combined with standard chemotherapy. CONCLUSIONS: The literature does not support the routine use of cetuximab as the standard first-line treatment of colorectal liver metastases, rather highlighting the need for the optimization of treatment on an individual basis, especially depending on tumourKRAS status.
Authors: J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson Journal: Nature Date: 1983 Aug 11-17 Impact factor: 49.962
Authors: S Giacchetti; M Itzhaki; G Gruia; R Adam; R Zidani; F Kunstlinger; S Brienza; E Alafaci; F Bertheault-Cvitkovic; C Jasmin; M Reynes; H Bismuth; J L Misset; F Lévi Journal: Ann Oncol Date: 1999-06 Impact factor: 32.976
Authors: Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard S Hochster; Scott Wadler; Paulo M Hoff; Nancy E Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen Journal: J Clin Oncol Date: 2007-09-17 Impact factor: 44.544
Authors: M Borner; D Koeberle; R Von Moos; P Saletti; D Rauch; V Hess; A Trojan; D Helbling; B Pestalozzi; C Caspar; T Ruhstaller; A Roth; A Kappeler; D Dietrich; D Lanz; W Mingrone Journal: Ann Oncol Date: 2008-03-17 Impact factor: 32.976
Authors: J Tol; M Koopman; C J Rodenburg; A Cats; G J Creemers; J G Schrama; F L G Erdkamp; A H Vos; L Mol; N F Antonini; C J A Punt Journal: Ann Oncol Date: 2008-02-13 Impact factor: 32.976
Authors: Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt Journal: N Engl J Med Date: 2009-02-05 Impact factor: 91.245
Authors: Richard A Adams; Angela M Meade; Matthew T Seymour; Richard H Wilson; Ayman Madi; David Fisher; Sarah L Kenny; Edward Kay; Elizabeth Hodgkinson; Malcolm Pope; Penny Rogers; Harpreet Wasan; Stephen Falk; Simon Gollins; Tamas Hickish; Eric M Bessell; David Propper; M John Kennedy; Richard Kaplan; Timothy S Maughan Journal: Lancet Oncol Date: 2011-06-05 Impact factor: 41.316
Authors: Floor C J van de Watering; Mark Rijpkema; Lars Perk; Ulrich Brinkmann; Wim J G Oyen; Otto C Boerman Journal: Biomed Res Int Date: 2014-05-28 Impact factor: 3.411